Sichuan Kangdesai Medical Technology

Sichuan Kangdesai Medical Technology is a clinical-stage biotechnology company based in Chengdu, China, specializing in the development of personalized immunotherapy for cancer. The company leverages its proprietary C-VAC platform to create patient-specific dendritic cell (DC) vaccines and mRNA-based therapies targeting neoantigens. Its lead candidate, CUD002, is a personalized DC vaccine currently in Phase I/II clinical trials for the treatment of recurrent ovarian cancer. Kangdesai's approach integrates high-throughput sequencing and bioinformatics to identify unique tumor mutations, aiming to provide precise and effective treatments for solid tumors. The company is also expanding its pipeline into mRNA-based cancer vaccines and other cell-based therapies.